Drug release from antithrombogenic multi-layer coated stent

Details Drug release from antithrombogenic multi-layer coated stent Drug release from antithrombogenic multi-layer coated stent

2004-03-09

2009-12-29

Meeks, Timothy H (Department: 1792)

Coating processes

Medical or dental purpose product; parts; subcombinations;...

Implantable permanent prosthesis

C427S002100, C427S002250, C623S001420, C623S001430, C623S001440, C623S001470

Reexamination Certificate

active

07638158

ABSTRACT:
A stent having a multi-layered coating adhered to its surface which can prevent restenosis and thrombosis at the implant site. The stent coating is comprised of two layers. The first layer is a polymeric coating with one or more biologically active agent(s) dispersed therein. The second layer is comprised of a hydrophobic heparinized polymer that inhibits blood coagulation and provides a hydrophilic surface for reducing the friction between stent and lesion site. In preferred embodiments of the invention, the multi-layered stent is effective in deterring restenosis and thrombosis at the implant site. In these same preferred embodiments, the multi-layered stent is capable of reducing the burst release of the biologically active agents from the first layer and sustaining a release of an effective amount of these agents for a relatively extended period of time. Methods of applying the multi-layered coating to the stent surface are also part of this invention.

REFERENCES:
patent: 4239754 (1980-12-01), Sache et al.
patent: 4857602 (1989-08-01), Casey et al.
patent: 5536508 (1996-07-01), Canal et al.
patent: 5626869 (1997-05-01), Nyqvist et al.
patent: 5700486 (1997-12-01), Canal et al.
patent: 5744155 (1998-04-01), Friedman et al.
patent: 5782908 (1998-07-01), Cahalan et al.
patent: 5820881 (1998-10-01), Milstein
patent: 5833651 (1998-11-01), Donovan et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 5840387 (1998-11-01), Berlowitz-Tarrant et al.
patent: 5855618 (1999-01-01), Patnaik et al.
patent: 5955588 (1999-09-01), Tsang et al.
patent: 5993846 (1999-11-01), Friedman et al.
patent: 5993972 (1999-11-01), Reich et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6190591 (2001-02-01), van Lengerich
patent: 6245753 (2001-06-01), Byun et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6251142 (2001-06-01), Bernacca et al.
patent: 6251428 (2001-06-01), Yoo
patent: 6258121 (2001-07-01), Yang et al.
patent: 6306144 (2001-10-01), Sydney et al.
patent: 6355058 (2002-03-01), Pacetti et al.
patent: 6361819 (2002-03-01), Tedeschi et al.
patent: 6376242 (2002-04-01), Hanson
patent: 6395253 (2002-05-01), Levy et al.
patent: 6399144 (2002-06-01), Dinh et al.
patent: 7129224 (2006-10-01), Byun et al.
patent: 2002/0091433 (2002-07-01), Ding et al.
patent: WO 00/13719 (2000-03-01), None
patent: WO 02/34312 (2002-05-01), None
Van Delden et al. The effect of protein adsorption on the anticoagulant activity of surface immobilized heparin, 1996, J. Biomaterial Science Polymer Edn. vol. 7, No. 8 pp. 727-740.
R. Altman et al. Oral Anticoagulant Treatment with and without Aspirin,Thrombosis and Haemostasis, 74, 506-510 (1995).
D. Brayden et al. Heparin Absorption Across the Intestine: Effects of SodiumN-[-(2-Hydroxybenzoyl)Amino]Caprylate in Rate In Situ Intestinal Instillations and in Caco-2 Monolayers,Pharmaceutical Research, 14, 1772-1779 (1997).
F. Diancourt et al. Chemical Modifications of Heparin. II. Hydrophobization of PartiallyN-Desulfated Heparin,Journal of Bioactive and Compatible Polymers, 11, 203-218 (1996).
R.D. Hull, MD et al. Hirudin versus heparin and low-molecular-weight heparin: And the winner is . . .J Lab Clin Med, 132, 171-174, (1998).
P. Klement et al. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model,J Lab Clin Med132, 181-185 (1998).
B.G. Koefoed et al. Effect of Fixed Minidose Warfarin, Conventional Dose Warfarin and Aspirin on INR and Prothrombin Fragment 1 + 2 in Patients with Atrial Fibrillation,Thrombosis and Haemostasis, 77, 845-848 (1997).
Y-k Lee, et al. Preparation of Slightly Hydrophobic Heparin Derivatives which Can Be Used for Solvent Casting in Polymeric Formulation,Thrombosis Research92, 149-156 (1998).
Y-k Lee et al. Oral Delivery of New Heparin Derivatives in Rats,Pharmaceutical Research, 17, 1-5 (2000).
A. Leone-Bay et al. 4-[4[(2-Hydroxybenzoyl)amino]phenyl]butyric Acid as a Novel Oral Delivery Agent for Recombinant Human Growth Hormone,J. Med. Chem., 39, 2571-2578 (1996).
A. Leone-Bay et al. The evolution of an oral heparin dosing solution,Drugs of the Future, 22, 885-891 (1997).
A. Leone-Bay et al. Oral Delivery of Sodium Cromolyn: Preliminary Studies In Vivo and In Vitro,Pharmaceutical Research, 13, 222-226 (1996).
A. Leone-Bay et al.N-Acylated α-Amino Acids as Novel Oral Delivery Agents for Proteins,J. Med. Chem., 38, 4263-4269 (1995).
A. Leone-Bay et al. Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP,Journal of Controlled Release, 50, 41-49 (1998).
A. Leone-Bay et al. Synthesis and Evaluation of Compounds That Facilitate the Gastrointestinal Absorption of Heparin,J. Med. Chem., 41, 1163-1171(1998).
A. Leone-Bay et al. Microsphere Formation in a Series of Derivatized α-Amino Acids: Properties, Molecular Modeling, and Oral Delivery of Salmon Calcitonin,J. Med. Chem., 38, 4257-4262 (1995).
S.J. Milstein et al. Partially unfolded proteins efficiently penetrate cell membranes—implications for oral drug delivery,Journal of Controlled Release, 53, 259-267 (1998).
G. E. Raskob, Msc. Low molecular weight heparin, heparin, and warfarin,Current Opinion in Hematology2, 372-379 (1995).
G.J. Russell-Jones, Carrier-Mediated Transport, Oral Drug Delivery, inEncyclopedia of Controlled Drug Delivery, 1, 173-183 (E. Mathiowitz, ed. 1999).
P. W. Swaan et al. Enhanced Transepithelial Transport of Peptides by Conjugation to Cholic Acid,Bioconjugate Chem. 8, 520-525 (1997).
L. Wallentin, Unstable coronary artery disease—need for long term antithrombotic treatment Aspirin alone is not sufficiant, I would associate an anticoagulant,Cardiovascular Research, 33, 292-294 (1997).
E. Windsor et al. Gastro-Intestinal Absorption of Heparin and Synthetic Heparinoids,Nature, 190, 263-264 (1961).

Affiliated with

Also associated with

Rating

Drug release from antithrombogenic multi-layer coated stent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Drug release from antithrombogenic multi-layer coated stent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug release from antithrombogenic multi-layer coated stent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4075109